Skip to main content

Seagen Inc.

SGENDelisted Dec 14, 2023
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001060736

Seagen Inc. was delisted on Dec 14, 2023; its insiders filed their last Form 4 on Dec 18, 2023; 614 institutions reported holding it in 13F filings for Q3 2023, worth $36.3B in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
614
Q3 2023, +29 vs. previous quarter
13F value
$36.3B
Reported value at the end of Q3 2023
Superinvestors holding
0
At the end of Q3 2023

From SEC filings, in USD.

Revenue, FY2022
$1.96B
+24.6% year over year
Net income, FY2022
-$610.3M
No comparable prior period
Free cash flow, FY2022
-$531.1M
No comparable prior period
Revenue, Q3 FY2023
$648.6M
+27.1% year over year

Revenue flow, FY2022

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2022: $610.3M (31.1% of revenue).

Superinvestors holding SGEN, Q3 2023

Go to the superinvestors tab

No superinvestor reported holding SGEN at the end of Q3 2023.

Latest insider trades

See all insider trades

Open-market purchases and sales by Seagen Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 13, 2023 (view filing)Nov 103 daysEpstein David RCEOSSale−10.6K$213.01−$2.26M−7.2%136.6K after
Nov 13, 2023 (view filing)Nov 94 daysHimes Vaughn BChief Technical OfficerSSale−8.79K$213.32−$1.87M−17.1%42.6K after2 lots
Sep 22, 2023 (view filing)Sep 211 dayDansey Roger DPresident, R&D & CMOSSale−71$206.50−$14.7K−0.1%116.7K after
Sep 22, 2023 (view filing)Sep 211 dayHimes Vaughn BChief Technical OfficerSSale−80$206.50−$16.5K−0.2%51.4K after
Sep 22, 2023 (view filing)Sep 211 dayLiu Jean IChief Legal OfficerSSale−64$206.50−$13.2K−0.1%84.4K after
Sep 22, 2023 (view filing)Sep 211 dayRomp Charles REVP, Commercial U.S.SSale−45$206.50−$9.29K−0.1%69.1K after
Sep 22, 2023 (view filing)Sep 211 daySimpson Todd EChief Financial OfficerSSale−80$206.50−$16.5K−0.1%128.7K after
Sep 8, 2023 (view filing)Sep 71 dayHimes Vaughn BChief Technical OfficerSSale−8.79K$205.76−$1.81M−14.6%51.4K after
Sep 1, 2023 (view filing)Aug 311 dayDansey Roger DPresident, R&D & CMOSSale−4.03K$206.97−$833.9K−3.5%111.8K after
Sep 1, 2023 (view filing)Aug 311 dayHimes Vaughn BChief Technical OfficerSSale−1.79K$206.97−$371.5K−3.4%51.4K after

Top 10 13F holders, Q3 2023

See all 614 holders

The largest institutional positions in Seagen Inc. at the end of Q3 2023; share changes are against Q2 2023.

Institutions holding SGEN in Q3 2023
InstitutionSharesValue% of portfolioChange in sharesAction
Baker Bros. Advisors LP44,554,162$9.45B54.48%00.0%Unchanged
Vanguard Group Inc13,321,042$2.83B0.07%+5,3840.0%Added
Pentwater Capital Management LP12,880,000$2.73B26.31%+3,250,500+33.8%Added
BlackRock Inc.12,051,745$2.56B0.07%+9,926+0.1%Added
Primecap Management Co6,261,798$1.33B1.12%+222,990+3.7%Added
State Street Corp3,359,408$712.7M0.04%+25,204+0.8%Added
Millennium Management LLC3,065,700$650.4M0.68%+1,432,165+87.7%Added
Norges Bank2,554,682$542.0M0.11%−152,337−5.6%Reduced
Davidson Kempner Capital Management LP2,459,732$521.9M8.04%+777,503+46.2%Added
Citadel Advisors LLC2,428,418$515.2M0.56%+1,666,890+218.9%Added

4 members of Congress reported 12 trades in Seagen Inc. since 2020. Newest filings:

  1. Josh Gottheimer

    House · NJ · Nov 11, 2023

    Sell$1K-$15K

  2. Josh Gottheimer

    House · NJ · Jul 11, 2023

    Sell (partial)$1K-$15K

  3. Josh Gottheimer

    House · NJ · Jun 11, 2023

    Sell (partial)$1K-$15K

  4. Daniel S. Goldman

    House · NY · Apr 17, 2023

    Buy$1K-$15K

  5. Peter Meijer

    House · MI · Dec 30, 2022

    Sell$796.67